Literature DB >> 18066751

Mid-myocardial fibrosis by cardiac magnetic resonance in patients with lamin A/C cardiomyopathy: possible substrate for diastolic dysfunction.

Subha V Raman1, Elizabeth A Sparks, Peter M Baker, Beth McCarthy, Charles F Wooley.   

Abstract

AIMS: We sought to identify patterns of myocardial fibrosis in vivo in patients with lamin cardiomyopathy, and to determine its functional significance. METHODS AND
RESULTS: Eleven patients sharing the identical mutation in LMNA without contraindication to magnetic resonance were identified from a 1016-member pedigree. Eight autopsy hearts from deceased relatives were reviewed. Patients and age-matched controls underwent cardiac magnetic resonance that included measures of cardiac function and late gadolinium enhancement (LGE). LGE-CMR identified midmyocardial fibrosis of the basal interventricular septum in 5 of 11 LMNA patients that was identical to that seen in 6 autopsy specimens of related genotype-positive family members; this was not present in any of 11 controls. LGE-CMR was positive in the 5 oldest patients in the cohort, age 46 +/- 6 years compared to 24 +/- 10 years for LGE-negative subjects (p = 0.003). Systolic function was abnormal in 2 subjects, both with myocardial fibrosis. LGE-positivity distinguished patients with diastolic dysfunction by mitral inflow velocities from those with normal diastolic function; these patients also had significant left atrial enlargement compared to controls (p < 0.05).
CONCLUSIONS: LGE-CMR can identify myocardial fibrosis under genetic control in vivo in patients with heritable cardiomyopathy similar in distribution to that observed at autopsy. Mid-myocardial fibrosis may form the substrate for diastolic dysfunction in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066751     DOI: 10.1080/10976640701693733

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  21 in total

Review 1.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

2.  Sudden cardiac death in a patient with lamin A/C mutation in the absence of dilated cardiomyopathy or conduction disease.

Authors:  Philipp Ehlermann; Stephanie Lehrke; Theano Papavassiliu; Benjamin Meder; Martin Borggrefe; Hugo A Katus; Rainer Schimpf
Journal:  Clin Res Cardiol       Date:  2011-02-16       Impact factor: 5.460

3.  Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation.

Authors:  Wei Wu; Mahendra D Chordia; Barry P Hart; E Sathyajith Kumarasinghe; Min K Ji; Ajay Bhargava; Michael W Lawlor; Ji-Yeon Shin; Fusako Sera; Shunichi Homma; Antoine Muchir; Uday R Khire; Howard J Worman
Journal:  Bioorg Med Chem       Date:  2016-12-09       Impact factor: 3.641

4.  Skeletal myopathy in a family with lamin A/C cardiac disease.

Authors:  Subha Ghosh; Rahul Renapurkar; Subha V Raman
Journal:  Cardiovasc Diagn Ther       Date:  2016-10

5.  Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.

Authors:  Caroline Le Dour; Wei Wu; Véronique Béréziat; Jacqueline Capeau; Corinne Vigouroux; Howard J Worman
Journal:  J Lipid Res       Date:  2016-11-14       Impact factor: 5.922

6.  Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene.

Authors:  Wei Wu; Antoine Muchir; Jian Shan; Gisèle Bonne; Howard J Worman
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

7.  Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy.

Authors:  Miia Holmström; Sari Kivistö; Tiina Heliö; Raija Jurkko; Maija Kaartinen; Margareta Antila; Eeva Reissell; Johanna Kuusisto; Satu Kärkkäinen; Keijo Peuhkurinen; Juha Koikkalainen; Jyrki Lötjönen; Kirsi Lauerma
Journal:  J Cardiovasc Magn Reson       Date:  2011-06-20       Impact factor: 5.364

8.  ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene.

Authors:  Maria Chatzifrangkeskou; Caroline Le Dour; Wei Wu; John P Morrow; Leroy C Joseph; Maud Beuvin; Fusako Sera; Shunichi Homma; Nicolas Vignier; Nathalie Mougenot; Gisèle Bonne; Kenneth E Lipson; Howard J Worman; Antoine Muchir
Journal:  Hum Mol Genet       Date:  2016-04-30       Impact factor: 6.150

9.  Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo.

Authors:  Antonella Moreo; Giuseppe Ambrosio; Benedetta De Chiara; Min Pu; Tam Tran; Francesco Mauri; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2009-09-03       Impact factor: 7.792

10.  Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?

Authors:  Michael D Puchalski; Richard V Williams; Bojana Askovich; C Todd Sower; Kan H Hor; Jason T Su; Nathan Pack; Edward Dibella; William M Gottliebson
Journal:  Int J Cardiovasc Imaging       Date:  2008-08-07       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.